Yu Hwa Choi, Young Ae Kang, Kwang Joo Park, Jae Chol Choi, Kwan Goo Cho, Da Yeon Ko, Jun Ho Ahn, Boram Lee, Eunsol Ahn, Yun Ju Woo, Kwangsoo Jung, Nan Yul Kim, Valerie A Reese, Sasha E Larsen, Susan L Baldwin, Steven G Reed, Rhea N Coler, Hyejon Lee, Sang-Nae Cho
INTRODUCTION: This randomized, double-blind, placebo-controlled, phase 2a trial was conducted to evaluate the safety and immunogenicity of the ID93 + glucopyranosyl lipid adjuvant (GLA)-stable emulsion (SE) vaccine in human immunodeficiency virus (HIV)-negative, previously Bacillus Calmette-Guérin (BCG)-vaccinated, and QuantiFERON-TB-negative healthy adults in South Korea. METHODS: Adults (n = 107) with no signs or symptoms of tuberculosis were randomly assigned to receive three intramuscular injections of 2 μg ID93 + 5 μg GLA-SE, 10 μg ID93 + 5 μg GLA-SE, or 0...
May 11, 2023: Infectious Diseases and Therapy